GlassScriptPhysician profile
Chastidy Larson Robb
NPI 1528541455
$6,067.97
in general payments reported to CMS, 2019-2025
27 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $886 · 2022: $1,301 · 2023: $1,183 · 2024: $1,146 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,880.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,433.68 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $1,099.29 | 2021-2025 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,026.73 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Grifols USA, LLC | $402.12 | 2021-2023 | Prolastin-C Liquid |
| Genzyme Corporation | $386.06 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $316.60 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $265.02 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Jazz Pharmaceuticals INC. | $258.23 | 2021-2025 | |
| United Therapeutics Corporation | $137.53 | 2021-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $103.10 | 2024-2025 | Tezspire |
| Electromed, INC. | $96.40 | 2025 | Smartvest |
| Axsome Therapeutics, INC. | $71.11 | 2023-2025 | Sunosi |
| Bayer Healthcare Pharmaceuticals INC. | $61.77 | 2021-2023 | |
| Gilead Sciences, INC. | $54.71 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $54.58 | 2024-2025 | Lumryz |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $44.69 | 2022-2023 | |
| Advanced Respiratory, INC | $44.09 | 2021 | |
| Glaxosmithkline, LLC. | $36.19 | 2025 | Nucala, Arexvy, Shingrix |
| Paratek Pharmaceuticals, INC. | $32.85 | 2021-2022 | |
| Baxter Healthcare | $21.59 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $20.87 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $20.83 | 2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $18.07 | 2025 | Glassia |
| Ani Pharmaceuticals, INC. | $16.98 | 2022 | |
| Chiesi USA, INC. | $16.02 | 2021 | |
| Olympus America INC. | $15.27 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chastidy Robb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.